Advertisement

Annals of Surgical Oncology

, Volume 14, Issue 2, pp 766–770 | Cite as

Asymptomatic Colorectal Cancer with Un-Resectable Liver Metastases: Immediate Colorectal Resection or Up-Front Systemic Chemotherapy?

  • Andrea MuratoreEmail author
  • Daria Zorzi
  • Hedayat Bouzari
  • Marco Amisano
  • Paolo Massucco
  • Elisa Sperti
  • Lorenzo Capussotti
Article

Abstract

Background

About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases. Resection of colorectal cancer in patients with moderate-severe symptoms is mandatory before starting chemotherapy. Surgical treatment of asymptomatic colorectal cancers is still a matter of discussion.

Methods

From January 2000 to December 2004, we prospectively collected data on 35 consecutive patients who were treated straightaway by chemotherapy without primary tumor resection. All patients underwent FOLFOX6 as first-line chemotherapy. The aim of the study was to evaluate the rate of surgical complications related to un-resected colorectal tumor.

Results

The mean interval between diagnosis and start of chemotherapy was 23.1 days (95% CI: 17.3–28.8). Fifteen of the 35 patients (42.9%) were down-staged to surgery; the mean interval between chemotherapy start and colon-rectum cancer resection was 6.5 months (95% CI: 5.5–7.5). None of them developed complications related to the primary tumor during chemotherapy. Of the other 20 patients who did not undergo any curative surgery, 16 received a second line chemotherapy and 10 a third line: six patients are alive and without intestinal symptoms (mean follow up 22.5 months, 95% CI: 11.2–33.9). Only one patient (2.8%) developed clinical signs of intestinal occlusion 5.6 months from the start of chemotherapy and required urgent colostomy.

Conclusions

The rate of complications related to the non-resected colorectal tumor is very low using oxaliplatin as first line chemotherapy. Non-operative management of asymptomatic colorectal cancers with un-resectable liver metastases is a safe approach.

Keywords

Colorectal cancer Liver metastases Surgical management Chemotherapy 

References

  1. 1.
    Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321:531–5CrossRefGoogle Scholar
  2. 2.
    Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663–669PubMedCrossRefGoogle Scholar
  3. 3.
    Joffe J, Gordon PH. Palliative resection for colorectal carcinoma. Dis Colon rectum 1981; 24:355–360PubMedCrossRefGoogle Scholar
  4. 4.
    Longo WE, Ballantyne GH, Bilchik AJ, Modlin IM. Advanced rectal cancer. What is the best palliation ? Dis Colon Rectum 1988; 31:842–847PubMedCrossRefGoogle Scholar
  5. 5.
    Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, Millis M, Posner MC. Initial presentation with stage IV colorectal cancer. How aggressive should we be? Arch Surg 2000; 135:530–535PubMedCrossRefGoogle Scholar
  6. 6.
    Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196:722–728. DOI: 10.1016/S1072-7515(03)00136-4PubMedCrossRefGoogle Scholar
  7. 7.
    Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6:651–657PubMedCrossRefGoogle Scholar
  8. 8.
    Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 2005; 92:1155–1160. DOI: 10.1002/bjs.5060PubMedCrossRefGoogle Scholar
  9. 9.
    Sarela AI, Guthrie JA, Seymourt MT, Ride E, Guillou PJ, O’Riordain S. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001; 88:1352–1356PubMedCrossRefGoogle Scholar
  10. 10.
    Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205–216PubMedCrossRefGoogle Scholar
  11. 11.
    Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986; 57:1866–1870PubMedCrossRefGoogle Scholar
  12. 12.
    Finan PJ, Marshall RJ, Cooper EH, Giles GR. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985; 72:373–7PubMedCrossRefGoogle Scholar
  13. 13.
    Goslin R, Steele G Jr, Zamcheck N, Mayer R, MacIntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982; 25:749–54PubMedCrossRefGoogle Scholar
  14. 14.
    Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141:586–9PubMedCrossRefGoogle Scholar
  15. 15.
    Moran MR, Rothenberger DA, Lahr CJ, Buls JG, Goldberg SM. Palliation for rectal cancer. Resection? Anastomosis? Arch Surg 1987; 122:640–643PubMedGoogle Scholar
  16. 16.
    Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Teniere P, Paillot B. Colorectal cancer with non-resectable synchronous metastases: should the primari tumor be resected? Gastroenterol Clin Biol 2004; 28:434–437PubMedCrossRefGoogle Scholar
  17. 17.
    Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005; 89:211–217PubMedCrossRefGoogle Scholar
  18. 18.
    Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingstone S, Andreyev J. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52:568–573PubMedCrossRefGoogle Scholar
  19. 19.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freqyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–2947PubMedGoogle Scholar
  20. 20.
    Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243–9249. DOI: 10.1200/JCO.2005.07.740PubMedCrossRefGoogle Scholar
  21. 21.
    Tournigand C, Andrè T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, landi B, Colin P,Louvet C, de Gramont A. FOLFIRI follone by FOLFOX6 or the riverse sequenze in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–237. DOI: 10.1200/JCO.2004.05.113PubMedCrossRefGoogle Scholar
  22. 22.
    Cohen AM. What is the best treatment for stage IV colorectal cancer? Ann Surg Oncol 2005; 12:581–582. DOI: 10.1245/ASO.2005.03.901PubMedCrossRefGoogle Scholar
  23. 23.
    Wichmann MW, Huttl TP, Winter H, Spelsberg F, Angele MK, Heiss MM, Jauch KW. Immunological effects of laparoscopic vs open colorectal surgery. Arch Surg 2005; 140:692–697PubMedCrossRefGoogle Scholar
  24. 24.
    Jarnagin WR, Delman K, Kooby D, Mastorides S, Zager J, Brennan MF, Blumgart LH, Federoff H, Fong Y. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg 2000; 231:762–71PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2006

Authors and Affiliations

  • Andrea Muratore
    • 1
    • 3
    Email author
  • Daria Zorzi
    • 1
  • Hedayat Bouzari
    • 1
  • Marco Amisano
    • 1
  • Paolo Massucco
    • 1
  • Elisa Sperti
    • 2
  • Lorenzo Capussotti
    • 1
  1. 1.Division of Surgical OncologyIstituto per la Ricerca e la Cura del CancroCandiolo (TO)Italy
  2. 2.Division of Medical OncologyIstituto per la Ricerca e la Cura del CancroCandiolo (TO)Italy
  3. 3.TorinoItaly

Personalised recommendations